Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes

• Main Authors: G. Tavares (Author), D. Marques (Author), C. Barra (Author), D. Rosendo-Silva (Author), A. Costa (Author), T. Rodrigues (Author), P. Gasparini (Author), B.F. Melo (Author), J.F. Sacramento (Author), R. Seiça (Author), S.V. Conde (Author), P. Matafome (Author)
• Format: Book
• Published: Elsevier, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background and objectives: The therapeutic effects of the dopamine D2 receptor (D2R) agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous system actions. However, peripheral dopamine directly modulates glucose uptake in insulin-sensitive tissues and lipid metaboli...